Nitto Avecia

What Nitto Avecia does

Nitto Avecia (operated through Nitto Avecia Pharma Services, Inc., a Delaware corporation headquartered at 10 Vanderbilt Avenue, Irvine, California) is a cGMP-compliant analytical testing and contract manufacturing organization focused on pharmaceutical, biotechnology, and medical device clients. The company operates from two adjacent buildings in Irvine covering 30,000 square feet of laboratory space and has been performing USP compendial methods since its inception in 1988, accumulating more than 30 years of operating history and thousands of validated analytical methods.

Its service portfolio spans Quality Control and Stability, Analytical Development and Validation, Compendial Testing (USP/EP/BP/JP), Elemental Impurity Analysis, Extractables and Leachables, Microbiological Testing, Protein and Gene Therapy Analysis (CAR-T, AAV, mAb, CRISPR), Bioassays/ELISA, and FTE staffing. The company is integrated with its sister entity Nitto Avecia (Nitto Denko Avecia), one of the world's larger oligonucleotide drug substance manufacturers with 25+ years of experience producing more than 1,200 oligonucleotide sequences, allowing end-to-end preclinical-to-commercial support for oligonucleotide programs.

Nitto Avecia generates revenue through project-based contracts, Full-Time Equivalent staffing, and Master Service Agreements sold via a direct enterprise sales motion and relationship-led business development. Customers include pharmaceutical and biotech sponsors (Phio Pharmaceuticals is publicly cited for commercial-scale PH-762 production), and the company maintains FDA-inspected, ICH-aligned cGMP compliance, completing a 2025 FDA inspection with zero Form 483 observations.

Name

Nitto Avecia

Legal name

Nitto Avecia Pharma Services, Inc.

Website

https://aveciapharma.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

101–250 employees

Short description

Nitto Avecia Pharma Services is a cGMP-compliant CDMO providing analytical testing and oligonucleotide manufacturing services to pharmaceutical, biotech, and medical device companies from FDA-inspected facilities in Irvine, California.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Analytical and Manufacturing Services (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract analytical services
• Oligonucleotide manufacturing
• Pharmaceutical CDMO
• Drug substance testing
• Biopharmaceutical analytical

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices2 records

Markets served

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Analytical Testing Services: Provides comprehensive analytical chemistry testing services for pharmaceutical and biotech companies including method development, validation, quality control, stability studies, compendial testing, elemental impurity analysis, extractables/leachables testing, and microbiological testing. Revenue is generated through project-based contracts with pharmaceutical clients.
2. Oligonucleotide Manufacturing Services: Drug substance oligonucleotide manufacturing services from preclinical through commercial scale through partnership with Nitto Avecia. Services include analytical method development and validation, stability studies, and product characterization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Nitto Avecia Pharma Services is a contract development and manufacturing organization (CDMO) providing analytical testing services to pharmaceutical, biotechnology, and medical device companies. Operating from FDA-inspected, cGMP-compliant facilities in Irvine, California, the company delivers a comprehensive suite of analytical services—including quality control, stability studies, analytical development, compendial testing, elemental impurities, extractables/leachables, microbiological testing, gene therapy analysis, and bioassays—integrated with parent Nitto Avecia's oligonucleotide drug substance manufacturing capabilities to provide end-to-end support from preclinical through commercial scale.

Product overview

Nitto Avecia Pharma Services is a single-source analytical testing and manufacturing services provider for pharmaceutical, biotech, and medical device industries. The company operates as a unified platform combining analytical services with GMP drug substance manufacturing through its partnership with Nitto Avecia. The service portfolio includes Quality Control & Stability Studies, Analytical Development, Oligonucleotide Services, Compendial Testing, Elemental Impurity Analysis, Extractables & Leachables Testing, Microbiological Testing, Protein & Gene Therapy Analysis, Bioassays and ELISA, and FTE Services. Together with Nitto Avecia's manufacturing capabilities, the company offers end-to-end support from preclinical development through commercial production.

Differentiator

Problem solved

Functional benefit

Products and services

• Analytical Services Comprehensive analytical testing services for pharmaceutical, biotech, and medical device companies covering the drug development lifecycle from analytical chemistry through quality control and stability studies.
• Quality Control & Stability Studies cGMP-validated photostability equipment and environmental chambers for protecting product quality, integrity, and security; includes stability study design, freeze/thaw studies, and stability indicating method development.
• Analytical Development & Validation Method development and validation services for pharmaceutical drug substances and drug products, supporting regulatory applications with gap analysis, remedial validation, and technology transfer.
• Oligonucleotide Services Integrated oligonucleotide solutions including analytical method development, validation, stability studies, and drug substance manufacturing from preclinical to commercial scale through the Nitto Avecia partnership.
• Compendial Testing USP, EP, BP, JP, and customer-specified monograph testing for drug substances, drug products, and various dosage forms including tablets, capsules, parenterals, and transdermal products.
• Elemental Impurity Analysis Elemental impurity testing compliant with USP <232>, <233> and ICH guidelines using ICP-MS, ICP-OES, Graphite AA, Flame AA, and Cold Vapor AA instrumentation.
• Extractables & Leachables Testing Container/closure system safety evaluation using a three-phase systematic approach including control extraction studies, model extraction studies, and leachable studies.
• Microbiological Testing cGMP microbiological testing including compendial methods, microbial limits, endotoxin testing (Gel-clot, Kinetic Chromogenic, Kinetic Turbidimetric), sterility testing, and environmental monitoring.
• Protein & Gene Therapy Analysis Gene therapy testing services for CAR-T, AAV, mAb, protein and CRISPR products including release testing, virus capsid testing, protein expression, genomic analysis, and guide RNA synthesis.
• Bioassays and ELISA Bioassay and cell-based assay services including Master and Working Cell Bank generation, cell culture, ELISA analyses, flow cytometry assays, kinase/phosphatase assays, and bioassay release testing.
• Full-Time Equivalent (FTE) Services Dedicated scientist staffing for client projects with FTE project staffing and hybrid resource models, providing analytical development, formulation development, and QC testing expertise.

Quantifiable outcome

• Successfully completed 2025 FDA inspection with zero Form 483 observations
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Phio PharmaceuticalscoreStrategic or Co-development Partner · 1 June 2025Drug substance services agreement for commercial-scale cGMP production of PH-762, Phio's lead drug candidate for intratumoral cancer treatment. Avecia conducted analytical development, method validation, and manufacturing services to support upcoming clinical trials following Phase 1b dose-escalation study completion.
• Nitto Denko CorporationcoreOthersNitto Avecia and Nitto Avecia Pharma Services operate as part of Nitto Group, sharing common vision of 'Creating Wonders.' Nitto Denko Avecia is the world's premier oligonucleotide manufacturer, working seamlessly with Nitto Avecia Pharma Services to provide integrated support.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Catalent: Catalent is a large global CDMO offering drug substance and drug product development across multiple modalities including oligonucleotides and biologics. It competes with Nitto Avecia for outsourced pharmaceutical manufacturing and analytical work, but operates at significantly broader scale across many sites and dosage forms.
• Thermo Fisher Scientific (Patheon): Thermo Fisher's Patheon CDMO business provides integrated drug development, manufacturing, and analytical services to pharma and biotech globally. It is comparable as a large, multi-site CDMO offering analytical testing alongside drug substance and drug product services similar to Nitto Avecia's combined model.
• Lonza: Lonza is a leading global CDMO with extensive small-molecule, biologic, and oligonucleotide manufacturing capabilities. It competes with Nitto Avecia in oligo CDMO and analytical services while offering far greater geographic reach and capacity.
• WuXi STA: WuXi STA is the small-molecule CDMO arm of WuXi AppTec, offering end-to-end development, manufacturing, and analytical services. It competes with Nitto Avecia for pharma outsourcing contracts, particularly in analytical and oligonucleotide-related work.
• Eurofins Scientific: Eurofins is a large contract testing organization providing analytical, microbiological, and pharmaceutical quality testing services. It overlaps directly with Nitto Avecia Pharma Services' analytical testing offering for pharma and biotech clients.
• Charles River Laboratories: Charles River provides discovery, safety assessment, and manufacturing services to the pharma and biotech industries, including biologics and cell/gene therapy testing. It is comparable as a CRO/CDMO with strong analytical and QC capabilities serving similar pharma customers.

Direct peers

• Curia (formerly AMRI): Curia is a CDMO offering small-molecule API manufacturing, analytical services, and drug product development for pharmaceutical companies. It directly competes with Nitto Avecia in contract analytical testing and CDMO services for small-molecule and complex therapeutics.
• Ajinomoto Bio-Pharma Services: Ajinomoto Bio-Pharma is a CDMO specializing in small-molecule API, oligonucleotide, and peptide manufacturing with integrated analytical services. It is a direct comparable to Nitto Avecia in oligo-focused CDMO and analytical offerings.
• Asymchem: Asymchem is a China-based CDMO offering small-molecule API development and manufacturing, including oligonucleotide and peptide capabilities. It competes with Nitto Avecia for outsourced pharma manufacturing programs targeting global pharma customers.

Regional players

• Element Materials Testing: Element is a global testing, inspection, and certification company with pharma and life-sciences analytical services. It is comparable as a contract testing organization serving pharma and biotech, though it does not provide oligonucleotide manufacturing like Nitto Avecia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/aveciapharma
• Facebookfacebook.com/aveciapharma
• LinkedInlinkedin.com/company/nitto-avecia-pharma-services

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nitto Avecia